XNASFBRX
Market cap33mUSD
Dec 27, Last price
22.92USD
1D
6.60%
1Q
299.30%
IPO
-99.53%
Name
Forte Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-1.14%
Rev. gr., 5y
-3.65%
Revenues
0k
Net income
-31m
L+127.07%
CFO
-29m
L+250.71%
Earnings
Mar 17, 2025
Profile
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 32,486 | 13,896 | 21,522 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (32,486) | (13,896) | (21,522) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (17) | (201) | |||||||
Tax Rate | |||||||||
NOPAT | (32,486) | (13,879) | (21,321) | ||||||
Net income | (31,476) 127.07% | (13,862) -36.14% | (21,708) -72.36% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 24,728 | 7,229 | 62 | ||||||
BB yield | -95.32% | -1.66% | -0.01% | ||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,153 | ||||||||
Net debt | (37,125) | (41,100) | (42,044) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (28,706) | (8,185) | (16,677) | ||||||
CAPEX | (88) | ||||||||
Cash from investing activities | 47 | ||||||||
Cash from financing activities | 24,684 | 7,241 | (44) | ||||||
FCF | (32,595) | (13,879) | (21,224) | ||||||
| Balance | |||||||||
Cash | 37,125 | 41,100 | 42,044 | ||||||
Long term investments | |||||||||
Excess cash | 37,125 | 41,100 | 42,044 | ||||||
Stockholders' equity | (118,480) | (87,023) | (73,150) | ||||||
Invested Capital | 153,794 | 125,841 | 114,698 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 1,263 | 17,384 | 13,968 | ||||||
Price | 20.54 -17.83% | 25.00 -53.27% | 53.50 -94.12% | ||||||
Market cap | 25,942 -94.03% | 434,588 -41.84% | 747,278 -88.84% | ||||||
EV | (11,183) | 393,488 | 748,540 | ||||||
EBITDA | (32,477) | (13,896) | (21,486) | ||||||
EV/EBITDA | 0.34 | ||||||||
Interest | 17 | ||||||||
Interest/NOPBT | |||||||||